Bacterial ecotin has the potential to reduce lung damage in cystic fibrosis (CF) by inhibiting the activity of an enzyme called neutrophil elastase without affecting the immune system’s ability to fight off infections, researchers found. Because the findings come from a small number of patient samples, “future work will…
News
Cells from the lungs of people with cystic fibrosis (CF) are less susceptible to infection by SARS-CoV-2, the COVID-19-causing virus, than those of people with other lung diseases, but they respond similarly to the influenza A virus, a study found. Restoring function to CFTR, the protein that’s faulty or…
The immune system of people with cystic fibrosis (CF) might be impaired due to long-term persistent lung infections and inflammation, a study suggested. Using a new and noninvasive standardized test for immune function called TruCulture, scientists found a lesser release of certain immune signaling proteins in immune cells from…
A new Cystic Fibrosis Innovation Hub has been launched in the U.K. to accelerate the development of new tests and treatments for lung infections in cystic fibrosis (CF) patients. This University of Liverpool-based hub will join a Translational Innovation Hub Network, which includes hubs led by the University of…
The balance of acids and bases in the urine of people with cystic fibrosis (CF) reflects lung and pancreas function, and the response to treatment, a study finds. The findings support measuring the bicarbonate base in urine, which mirrors the levels of various acids, as a tool to clinically…
A Phase 1b study that’s evaluating the safety of RCT2100, ReCode Therapeutics‘ investigational genetic medicine for people with cystic fibrosis (CF), has dosed its first patient. The inhalation therapy is being developed for CF patients who don’t respond to CFTR modulator therapies. “The initiation of our Phase…
A next-generation vest to help clear airway mucus in adults and children with cystic fibrosis (CF) or other lung disorders has been launched by its maker, Baxter International. Called The Vest Advanced Pulmonary Experience (APX), the garment was redesigned in consultation with clinicians and patients, and incorporates the…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to ETD001, an investigational therapy aiming to improve mucus clearance in people with cystic fibrosis (CF). The designation is awarded by the FDA to aid the development of treatments for serious or life-threatening rare diseases —…
Mucus-producing cells in people with cystic fibrosis (CF) have lower levels of ST3Gal1, an enzyme that sugarcoats mucus to make it less thick and sticky, but treatment with Trikafta can partly restore the enzyme and make mucus easier to clear away. The findings, from a study led by…
Non-white Canadians with cystic fibrosis (CF) have a higher risk of death than white Canadians with the disease, according to a study of nearly 6,000 people with CF. Despite having similar characteristics at diagnosis and similar rates of CF complications, non-white CF patients also had worse lung function,…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.